Approved drugs encompass a range of targeted treatments, including monoclonal antibodies that enhance the immune recognition of cancer cells (e.g., rituximab and cetuximab for non-Hodgkin lymphoma and colorectal cancer, respectively), tyrosine kinase inhibitors that hinder cancer cell growth (e.g., Imatinib, a BCR-Abl inhibitor), and inhibitors targeting protein complexes (such as proteasome inhibitors and mTOR inhibitors).6 This evidence concerns the gene MTOR and cancer.